MorphoSys will license Genedata Biologics as its R&D data management platform, to support the former's internal and partner-based biologics discovery programs for lead finding and optimisation. Genedata Biologics integrates with the MorphoSys laboratory infrastructure and interacts with discovery technologies, including the MorphoSys HUCAL antibody library, screening, and expression platforms.
'Therapeutic antibodies are one of the fastest-growing drug classes in human healthcare,' said Dr Markus Enzelberger, vice president and head of Discovery Alliances and Technologies at MorphoSys. 'To advance our leadership in this field, our biopharma R&D operations require an integrated and scalable informatics infrastructure that can be tailored to support our biologics discovery processes. Genedata Biologics provides comprehensive biologics data management functionality and the flexibility needed to support our proprietary antibody discovery processes and technology portfolio. And, it provides this functionality out-of-the-box, which saves valuable research time and money.'
